Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characteristics of Patients With Sickle Cell Disease Who Initiate Crizanlizumab Therapy

NCT05494541 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05494541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05494541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characteristics of Patients With Sickle Cell Disease Who Initiate Crizanlizumab Therapy
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
August 30, 2021
Completion date
October 27, 2021
Enrollment
540 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease